Periodic Reporting for period 2 - ReLink (Prevention of injuries to patients and nurses due to intravenous line dislodgement)
Período documentado: 2021-09-01 hasta 2023-04-30
The need for quality healthcare constantly grows as the global population and life expectancy increases. At the same time, hospitals struggle with budget deficits, personnel shortages, and stressful working environments. Tada Group’s innovation ReLink aims to significantly contribute to a sustainable, efficient, affordable, and safe healthcare system of tomorrow. Intravenous (IV) therapy is the most common invasive treatment in the world received by 90% of in-hospital patients. However, around 10% of all IV lines are accidentally ripped from the patient’s vein during treatment, i.e. IV dislodgement. This results in consequences such as loss of medication, interrupted therapy, patient injury, and increased personnel workload. Our patented technology, ReLink targets the safety issues with accidental dislodgement of IV lines. Its breakaway connector approach significantly reduces the risk for dislodgement, and its unique design minimises the adverse consequences.
ReLink keeps patients and nurses safe, supports accurate drug delivery, saves nursing time and makes IV therapy safer, more accurate and efficient. This proposition plays out in multiple ways for our stakeholders.
• Patients - Significantly enhanced safety, reduction of injuries, improved accuracy of treatment.
• Nurses – Improved workplace safety through less spill of potentially hazardous drugs and contaminated blood. Increased efficiency (90% reduction in number of hours to manage IV disconnections - estimated to be over 90,000 hours annually in Europe and US).
• Hospitals - Cost reduction, improved nursing efficiency, reduced risk of legal liabilities towards emerging regulations for workplaces hazards, reduced plastic waste.
• Payers - Reduction in treatment costs.
• OEM partners – Improve competitiveness of the IV infusion product portfolio, opportunity to integrate ReLink in their portfolio and offer a differentiated solution in a mature market. Improve price realisation. Offer efficiency, a better infection protection solution and reduced bedside time for care to your healthcare partners (a need highlighted by the COVID-19 pandemic).
The main objective of the project is to evolve the Tada Group´s breakaway connector ReLink from its current prototype phase to a market ready product. The project is divided into five work packages, sub-objectives for these are 1) prototyping and production of ReLink devices for testing and demonstrations, 2) ISO 13485 certification and regulatory approval, 3) extended patent protection, 4) dissemination through conference contributions, trade fairs, press releases, white papers etc., 5) project management.
ReLink keeps patients and nurses safe, supports accurate drug delivery, saves nursing time and makes IV therapy safer, more accurate and efficient. This proposition plays out in multiple ways for our stakeholders.
• Patients - Significantly enhanced safety, reduction of injuries, improved accuracy of treatment.
• Nurses – Improved workplace safety through less spill of potentially hazardous drugs and contaminated blood. Increased efficiency (90% reduction in number of hours to manage IV disconnections - estimated to be over 90,000 hours annually in Europe and US).
• Hospitals - Cost reduction, improved nursing efficiency, reduced risk of legal liabilities towards emerging regulations for workplaces hazards, reduced plastic waste.
• Payers - Reduction in treatment costs.
• OEM partners – Improve competitiveness of the IV infusion product portfolio, opportunity to integrate ReLink in their portfolio and offer a differentiated solution in a mature market. Improve price realisation. Offer efficiency, a better infection protection solution and reduced bedside time for care to your healthcare partners (a need highlighted by the COVID-19 pandemic).
The main objective of the project is to evolve the Tada Group´s breakaway connector ReLink from its current prototype phase to a market ready product. The project is divided into five work packages, sub-objectives for these are 1) prototyping and production of ReLink devices for testing and demonstrations, 2) ISO 13485 certification and regulatory approval, 3) extended patent protection, 4) dissemination through conference contributions, trade fairs, press releases, white papers etc., 5) project management.
The project has brought Tada Group’s ReLink technology from TRL 6 to TRL 8. Through required regulatory work aligned with patient safety, ReLink is now a scalable commercial technology that will save the healthcare sector money, time and pain. Aligning with the 2030 agenda for sustainable development, ReLink brings about many societal impacts. Several of the goals stated by the EU commission will be enabled by ReLink, specifically patient safety and sustainability.
Major project achievements have been made withing R&D, device production, IPR filing, CE marking, Quality Management System ISO certification, commercialisation, awareness raising, and dissemination of project results.
Tada's Quality Management System has been certified as per ISO 13485:2016 and the ReLink device is commercially ready, including CE mark and technical and commercial marketing material. Production of the device has been validated for low-scale production and preparations for scaling to medium-size production have been made. ReLink is a platform technology, its many benefits make it attractive for several niche market areas as well as to be adopted into the general standard of care.
During the progress of the project, the patent for the ReLink technology has been extended into more than ten more countries and several new patent and trademark applications have been submitted and approved.
Several new team members have been recruited throughout the project. In late 2022, the company closed an investment round as a part of the preparation for the commercialisation phase.
Our marketing materials and commercialisation activities are all based on showcasing ReLink through different platforms whether it be scientific conferences, trade fairs, exhibitions, pitching events, investors meetings, workshops, or any other educational events. We have an impressive track record of participation in exhibitions, trade fairs and pitch events and are an active member of several networks both in Sweden and in Europe. Some examples of venues where ReLink has been presented include MEDICA, Arab Health, FIME - the Americas' leading medical trade fair and exhibition, World Congress on Vascular Access (WoCoVA), Infusion Nurses Society (INS) Annual Meeting & Exhibition, Annual Anglonordic Life Science Conference, Pan-European Hospital & Healthcare Procurement Summit, TechArenan summit, the Oncology Nursing Society's annual conference ONS Congress, and the World Innovation Summit for Health (WISH) where ReLink won first prize in the Booster Category.
Major project achievements have been made withing R&D, device production, IPR filing, CE marking, Quality Management System ISO certification, commercialisation, awareness raising, and dissemination of project results.
Tada's Quality Management System has been certified as per ISO 13485:2016 and the ReLink device is commercially ready, including CE mark and technical and commercial marketing material. Production of the device has been validated for low-scale production and preparations for scaling to medium-size production have been made. ReLink is a platform technology, its many benefits make it attractive for several niche market areas as well as to be adopted into the general standard of care.
During the progress of the project, the patent for the ReLink technology has been extended into more than ten more countries and several new patent and trademark applications have been submitted and approved.
Several new team members have been recruited throughout the project. In late 2022, the company closed an investment round as a part of the preparation for the commercialisation phase.
Our marketing materials and commercialisation activities are all based on showcasing ReLink through different platforms whether it be scientific conferences, trade fairs, exhibitions, pitching events, investors meetings, workshops, or any other educational events. We have an impressive track record of participation in exhibitions, trade fairs and pitch events and are an active member of several networks both in Sweden and in Europe. Some examples of venues where ReLink has been presented include MEDICA, Arab Health, FIME - the Americas' leading medical trade fair and exhibition, World Congress on Vascular Access (WoCoVA), Infusion Nurses Society (INS) Annual Meeting & Exhibition, Annual Anglonordic Life Science Conference, Pan-European Hospital & Healthcare Procurement Summit, TechArenan summit, the Oncology Nursing Society's annual conference ONS Congress, and the World Innovation Summit for Health (WISH) where ReLink won first prize in the Booster Category.
The project’s overall work plan has ensured the achievement of a set of well-defined technology and market maturation activities which have advanced the ReLink technology from prototype phase to being commercially ready for scaling with regards to both production and sales.
ReLink is the result of our work together with end users to ensure that our product fits their existing needs, while providing effective and accessible patient and user protection. The value proposition of ReLink is to provide an improvement in patient safety, saving valuable nursing time spent by the patient bedside as well as improve nurses’ work environment by prohibiting spill of hazardous drugs.
Our scale up strategy has a significant post-project potential of job creation in the value chain. The project has not only focused on fulfilment of a global unmet healthcare need, but also shaping a focused plan to bring a financially viable and sustainable medical device to the market. Our market-ready product ReLink brings together a product that solves the need of the end users, promotes global business growth, and brings measurable benefits to the society.
ReLink is the result of our work together with end users to ensure that our product fits their existing needs, while providing effective and accessible patient and user protection. The value proposition of ReLink is to provide an improvement in patient safety, saving valuable nursing time spent by the patient bedside as well as improve nurses’ work environment by prohibiting spill of hazardous drugs.
Our scale up strategy has a significant post-project potential of job creation in the value chain. The project has not only focused on fulfilment of a global unmet healthcare need, but also shaping a focused plan to bring a financially viable and sustainable medical device to the market. Our market-ready product ReLink brings together a product that solves the need of the end users, promotes global business growth, and brings measurable benefits to the society.